Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

ACR/ARHP Annual Meeting 2012: Physicians Find Treatment Options Limited for Scleroderma Bowel Disease

Thomas R. Collins  |  Issue: March 2013  |  March 1, 2013

WASHINGTON, D.C.—The first treatment option for most kinds of scleroderma bowel disease, or gastrointestinal involvement related to scleroderma, is lifestyle change—but proven medical treatments are hard to come by and are severely understudied in this disorder, an expert said at the 2012 ACR/ARHP Annual Meeting, held here November 9–14. [Editor’s Note: This session was recorded and is available via ACR SessionSelect at www.rheumatology.org.]

Most of the medical treatments do not come with a long track record, said John Clarke, MD, clinical director of the Center for Neurogastroenterology at Johns Hopkins University in Baltimore, in a session titled, “Scleroderma Bowel Disease: From Top to Bottom.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Scleroderma is a systemic process, and the gastrointestinal (GI) tract is the largest organ system in the body except for the skin, so it shouldn’t be surprising that GI involvement is the most frequent internal complication. The esophagus is the most commonly affected organ, but any part of the GI system can be involved, with symptoms from dysphagia to heartburn, vomiting to incontinence. And the complications can be very serious. Severe GI involvement is seen in only about 8% of cases, but among those, only 15% survive more than nine years, Dr. Clarke said.

“Scleroderma does affect the gut within the vast majority of cases,” Dr. Clarke said. “Treatment is geared primarily toward decreasing reflux, reducing the complications associated with it, enhancing gastrointestinal function, avoiding bacterial overgrowth, and optimizing nutrition. Treatments at this point are mainly reactive in nature.” He offered treatment guidance for a variety of symptoms and conditions related to scleroderma bowel disease:

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Oropharyngeal

Treatment is limited to lifestyle changes—small bolus sizes, soft foods, liquid supplementation, and dental follow-up.

Esophageal Dysmotility

“Treatment can be somewhat challenging,” Dr. Clarke said. “The scleroderma-specific therapies haven’t been shown to make a difference in terms of gastrointestinal dysfunction. The goal of treatment is certainly to reduce symptoms as well as treat any complications that arise.”

Patients should avoid foods known to slow gastric emptying or decrease sphincter pressure, such as chocolate, high-citrus fruits and juices, onions, garlic, and caffeine. Quitting smoking, avoiding alcohol, elevating the head when sleeping, sleeping on the left side, and not eating within three hours of sleeping are also recommended.

Medically, proton-pump inhibitors are the mainstay, “by far the most effective, but also the most expensive,” Dr. Clarke said. Prokinetics are not great options, but the EULAR Scleroderma Trials and Research (EUSTAR) consensus in 2009 recommended considering them, he said.1

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsMeeting Reports Tagged with:ACR/ARHP Annual MeetingClinicalscleroderma bowel diseaseTreatment

Related Articles

    Treatments for Scleroderma with Gastrointestinal Involvement Address Symptoms

    June 13, 2016

    CHICAGO—Nine out of 10 scleroderma cases include clinical signs of gastrointestinal (GI) involvement, with severe involvement associated with high mortality rates, but the pathology of this is not very well understood, a GI expert said at the ACR’s State-of-the-Art Clinical Symposium. That has left clinicians with a slate of treatments—anti-reflux, antimicrobials and prokinetics—that address only…

    Lost and found

    The History of ACE Inhibitors in Scleroderma Renal Crisis

    February 16, 2021

    Scleroderma renal crisis is a true medical emergency in rheumatology, one that requires prompt diagnosis and treatment. Here, we review the historic introduction of the angiotensin-converting enzyme inhibitors in this context, and highlight management and key questions moving forward. Background Awareness of renal disease in scleroderma dates back many years. The revered physician William Osler…

    Diffuse Scleroderma: A 1991 Case Through the Lens of Today

    Diffuse Scleroderma: A 1991 Case Through the Lens of Today

    February 17, 2018

    The year was 1991. It was my first Tuesday as a rheumatology fellow at the University of Pittsburgh’s Presbyterian Hospital. Navigating a maze of buildings and hallways, I delivered myself to the entrance to the scleroderma clinic. Running late and not knowing whether there was a separate entrance for staff, I clicked open the door….

    Scleroderma & the Gut: New Frontiers in Diagnosis & Tips on Management

    May 12, 2022

    McMahan et al. examined how abnormal gastrointestinal (GI) transit may contribute to GI severity and symptoms in patients with systemic sclerosis (SSc). About 90% of people with SSc have GI tract involvement, and understanding the connection between GI symptoms, their severity and abnormal GI transit may permit targeted therapeutic approaches for these patients.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences